-
Article
Open AccessPrediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer
No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests bu...
-
Article
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genoty**
De novo metastatic prostate cancer is highly aggressive, but the paucity of routinely collected tissue has hindered genomic stratification and precision oncology. Here, we leveraged a rare study of surgical in...
-
Article
Open AccessA generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes
Specific classes of DNA damage repair (DDR) defect can drive sensitivity to emerging therapies for metastatic prostate cancer. However, biomarker approaches based on DDR gene sequencing do not accurately predi...
-
Article
Open AccessCombined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer
Both changes in circulating lipids represented by a validated poor prognostic 3-lipid signature (3LS) and somatic tumour genetic aberrations are individually associated with worse clinical outcomes in men with...
-
Article
Open AccessThe MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology
Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish a significant resource of patient-derived xenografts (PDXs) of prostate cancer for rapid and systematic evaluation...
-
Article
Open AccessDetection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression
DNA originating from degenerate tumour cells can be detected in the circulation in many tumour types, where it can be used as a marker of disease burden as well as to monitor treatment response. Although circu...
-
Article
Cell-free DNA in cancer: current insights
The field of liquid biopsies in oncology is rapidly expanding, with the application of cell-free circulating tumour DNA (ctDNA) showing promise in this era of precision medicine. Compared with traditional clin...
